We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 3, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel Corp. (INTC - Free Report) , Anheuser-Busch InBev SA/NV (BUD - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) , Moderna, Inc. (MRNA - Free Report) and DuPont de Nemours, Inc. (DD - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Intel, Anheuser-Busch and HCA Healthcare
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Intel Corp., Anheuser-Busch InBev SA/NV and HCA Healthcare, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Intel shares have lagged the Zacks Semiconductor industry this year (+35.7% vs. +69.1%), but they have handily outperformed the broader (+35.7% vs. +12.9% for the S&P 500 index). The company is focusing on establishing an advanced semiconductor manufacturing ecosystem and has expanded its production capabilities in Germany and Poland under its IDM 2.0 (integrated device manufacturing) strategy.
A concerted focus on increasing market diversification and healthy momentum in data center business are tailwinds. Intel is also expanding its foundry services through partnership with Tower Semiconductor. The launch of its glass substrates for advanced packaging of chips is another positive.
However, contraction in the total addressable market across all CPU market segments is a major headwind. Weak demand trends and sluggish recovery in China are hurting sales in Network and Edge Group. Macroeconomic challenges, inventory adjustments and intense market volatility are straining margins.
Shares of Anheuser-Busch have outperformed the Zacks Beverages - Alcohol industry over the past year (+17.9% vs. -4.1%). The company has been benefiting from continued consumer demand for its brand portfolio. The company’s relentless execution, investment in brands and accelerated digital transformation aided top-line growth in second-quarter 2023.
The top line also benefited from strength of the beer category globally. The expansion of the Beyond Beer portfolio, and investments in B2B platforms, e-commerce and digital marketing bode well. For 2023, AB InBev expects EBITDA growth of 4-8%, in line with our estimate of 4%. It anticipates revenue growth to be higher than EBITDA growth, compared to our estimate 6% growth.
However, shares of AB InBev lagged the industry year to date. The stock came under pressure due to dismal earnings in the second quarter. AB InBev’s EBIT margin declined in the second-quarter, driven by higher cost of sales and SG&A expenses.
HCA Healthcare shares have outperformed the Zacks Medical - Hospital industry over the past year (+28.4% vs. +23.7%). The company’s revenues remain on an uptick on the back of a surge in admissions, outpatient surgeries and other procedures. Significant growth in its Managed Medicare operations is expected to drive its performance.
Multiple buyouts aided it in increasing patient volumes, enabled network expansion and added hospitals to its portfolio. It has been gaining from its telemedicine business line on the back of the rising digitization trend. HCA Healthcare resorts to prudent capital deployment via share buybacks and dividend payments.
However, the company's escalating operating expenses have been weighing on the margins. A high debt level induces rise in interest expenses. As such, the stock warrants a cautious stance.
Other noteworthy reports we are featuring today include Moderna, Inc. and DuPont de Nemours, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours
For Immediate Release
Chicago, IL – October 3, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel Corp. (INTC - Free Report) , Anheuser-Busch InBev SA/NV (BUD - Free Report) , HCA Healthcare, Inc. (HCA - Free Report) , Moderna, Inc. (MRNA - Free Report) and DuPont de Nemours, Inc. (DD - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Intel, Anheuser-Busch and HCA Healthcare
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Intel Corp., Anheuser-Busch InBev SA/NV and HCA Healthcare, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Intel shares have lagged the Zacks Semiconductor industry this year (+35.7% vs. +69.1%), but they have handily outperformed the broader (+35.7% vs. +12.9% for the S&P 500 index). The company is focusing on establishing an advanced semiconductor manufacturing ecosystem and has expanded its production capabilities in Germany and Poland under its IDM 2.0 (integrated device manufacturing) strategy.
A concerted focus on increasing market diversification and healthy momentum in data center business are tailwinds. Intel is also expanding its foundry services through partnership with Tower Semiconductor. The launch of its glass substrates for advanced packaging of chips is another positive.
However, contraction in the total addressable market across all CPU market segments is a major headwind. Weak demand trends and sluggish recovery in China are hurting sales in Network and Edge Group. Macroeconomic challenges, inventory adjustments and intense market volatility are straining margins.
(You can read the full research report on Intel here >>>)
Shares of Anheuser-Busch have outperformed the Zacks Beverages - Alcohol industry over the past year (+17.9% vs. -4.1%). The company has been benefiting from continued consumer demand for its brand portfolio. The company’s relentless execution, investment in brands and accelerated digital transformation aided top-line growth in second-quarter 2023.
The top line also benefited from strength of the beer category globally. The expansion of the Beyond Beer portfolio, and investments in B2B platforms, e-commerce and digital marketing bode well. For 2023, AB InBev expects EBITDA growth of 4-8%, in line with our estimate of 4%. It anticipates revenue growth to be higher than EBITDA growth, compared to our estimate 6% growth.
However, shares of AB InBev lagged the industry year to date. The stock came under pressure due to dismal earnings in the second quarter. AB InBev’s EBIT margin declined in the second-quarter, driven by higher cost of sales and SG&A expenses.
(You can read the full research report on Anheuser-Busch here >>>)
HCA Healthcare shares have outperformed the Zacks Medical - Hospital industry over the past year (+28.4% vs. +23.7%). The company’s revenues remain on an uptick on the back of a surge in admissions, outpatient surgeries and other procedures. Significant growth in its Managed Medicare operations is expected to drive its performance.
Multiple buyouts aided it in increasing patient volumes, enabled network expansion and added hospitals to its portfolio. It has been gaining from its telemedicine business line on the back of the rising digitization trend. HCA Healthcare resorts to prudent capital deployment via share buybacks and dividend payments.
However, the company's escalating operating expenses have been weighing on the margins. A high debt level induces rise in interest expenses. As such, the stock warrants a cautious stance.
(You can read the full research report on HCA Healthcare here >>>)
Other noteworthy reports we are featuring today include Moderna, Inc. and DuPont de Nemours, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.